The aim of immunotherapy is to treat obstinate diseases, such as cancer, infectious diseases or autoimmune diseases by stimulating immune responses or suppressing harmful immune responses. Due to their selectivity and low toxicity, the immunotherapeutic agents become prominent as the next generation drugs. Furthermore, the therapeutic effect of chemotherapy or surgery is expected to be improved by combination with them. Here, we have developed 2 antibodies, 3 therapeutic vaccines and 2 cytokine/cytokine receptor. We produced HBV-neutralizing human monoclonal antibody and RSV-neutralizing human monoclonal antibody to prevent viral infection. Therapeutic vaccines for treatment of Her-2/neu overexpressing cancer, chronic HCV-infection or CEA-expressing solid cancer have developed and produced in accordance with good manufacturing practice. A new TNFR-Fc fusion protein for treatment of rheumatoid arthritis and a new G-CSF conjugate for treatment of neutrophenia were developed to improve in vivo stability and bioactivity.
저자
Chang-Yuil Kang [ Laboratory of Immunology, Institute of Pharmaceutical Sciences, College of Pharmacy, Department of Molecular Medicine and Biopharmaceutical Science, Graduate School of Convergence Science and Technology, Seoul National University ]
한국생물공학회 [The Korean Society for Biotechnology and Bioengineering]
설립연도
1984
분야
공학>생물공학
소개
이 법인은 생물 공학의 발전과 보급에 이바지하고, 회원 상호 간의 연구 협력과 친목을 도모함을 목적으로 한다
1. 생물공학 분야의 발전을 위한 연구 협력
2. 생물공학의 실용화를 촉진시키기 위한 산학 협동
3. 학술연구 발표회, 강연회, 연수회 등 학술활동의 개최
4. 국,영문 학술지,소식지,학술회의 Proceedings 및 학술도서의 발간
5. 생물공학 발전을 위한 정책 건의
6. 기타 국제 교류 등 본 학회의 목적 달성을 위한 제반 활동